• Pepstatin A in Necroptosis Assays

  2026-09-07

  Pepstatin A is a selective aspartic protease inhibitor that can sharpen interpretation of lysosomal membrane permeabilization experiments. This article explains why its value in necroptosis research lies in distinguishing cathepsin D-associated activity from the cathepsin B mechanism identified in recent MLKL studies.

• Anti-HMGB1 Rabbit Monoclonal Antibody Guide

  2026-09-07

  The Anti-HMGB1 Rabbit Monoclonal Antibody (MA3057) supports research detection of HMGB1 in human, mouse, and rat samples by Western blot, immunohistochemistry, and flow cytometry. It is intended for controlled scientific workflows only and should not be used for diagnosis, patient testing, or therapeutic decisions.

• Cytoskeleton-Dependent Autophagy Under Compression

  2026-09-05

  The reference study shows that compression-induced autophagy in human cells depends mainly on microfilaments, while microtubules provide an auxiliary contribution. Its pharmacological and imaging-based design offers a useful framework for separating force-bearing cytoskeletal functions from downstream autophagy responses.

• Cyclic Pifithrin-α Hydrobromide: p53 Inhibition

  2026-09-04

  Cyclic Pifithrin-α hydrobromide is a p53 inhibitor for experimental studies of p53-dependent transactivation, apoptosis, growth arrest, and radiation response. Its strongest evidence supports controlled in vitro pathway perturbation and preclinical radioprotection research, not clinical cancer therapy or medical use.

• Z-VDVAD-FMK for Caspase-2 Pathway Mapping

  2026-09-04

  Z-VDVAD-FMK helps researchers separate caspase-2-, caspase-3-, and caspase-7-linked apoptosis from caspase-1-driven pyroptosis. Its cell permeability and irreversible target engagement make it useful for mitochondrial apoptosis workflows, cancer research, and mechanistic validation of cell-death phenotypes.

• Temafloxacin Against Gram-Negative Bacteria

  2026-09-03

  Hardy’s reference study synthesizes comparative in vitro susceptibility data for temafloxacin, ciprofloxacin, and ofloxacin across respiratory, sexually transmitted, enteric, and opportunistic Gram-negative pathogens. Its main contribution is a spectrum-level interpretation of MIC patterns, including strong activity against many respiratory organisms and a clear limitation against Pseudomonas aeruginosa.

• CGRP/SP–Piezo2 Signaling in Trigeminal Allodynia

  2026-09-03

  Liao et al. identify a calcium-dependent CGRP/SP–Piezo2 feedback loop linking trigeminal root compression, neuroinflammation, and mechanical allodynia. Their rat and cell-based experiments position ATP, PKC, ERK1/2, and p38 MAPK signaling along the trigeminal ganglion–Merkel cell axis as mechanistic targets for studying trigeminal neuralgia.

• Reelin Signaling Enables Ketamine Synaptic Action

  2026-09-02

  The reference study identifies Reelin–Apoer2–Src family kinase signaling as a permissive pathway for ketamine-induced hippocampal plasticity and behavioral effects. By combining genetic disruption, pharmacological inhibition, electrophysiology, and behavioral analysis, the work links ketamine nonresponsiveness to impaired baseline NMDA receptor function rather than to a simple failure of acute downstream pathway activation.

• Isorhamnetin: PI3K/Akt and Oocyte Stress

  2026-09-02

  Isorhamnetin is a flavonoid compound that improved porcine oocyte maturation in a published 44-hour in vitro study through PI3K/Akt activation and reduced cellular stress. This article distinguishes the reported 10 µM benchmark from exploratory applications in oxidative stress research, apoptosis assays, and pathway biology.

• Acetylcysteine: Mechanism and Research Guide

  2026-09-01

  Acetylcysteine, also called N-acetyl-L-cysteine or NAC, supplies cysteine for glutathione biosynthesis and can chemically modify oxidants and mucus disulfide bonds. This guide defines its mechanism, product parameters, research applications, and limits using peer-reviewed and product-level evidence.

• Lumiracoxib and the Timing of COX-2 Biology

  2026-09-01

  Lumiracoxib is more than a potent selective COX-2 inhibitor: it is a practical tool for resolving when cyclooxygenase-2 pathway modulation protects injured tissue or reshapes its recovery. This article translates recent muscle ischemia and revascularization findings into a rigorous workflow for mechanistic and translational researchers.

• Lumiracoxib Workflows for COX-2 Research

  2026-08-31

  Lumiracoxib enables selective COX-2 pathway interrogation in inflammation, ischemia, and muscle-repair models without treating COX-1 biology as an uncontrolled confounder. A time-staged workflow based on venom-induced muscle injury helps distinguish early vascular protection from later proangiogenic effects.

• Mianserin HCl: From Trial Design to Receptor Logic

  2026-08-31

  Mianserin HCl is more than a historical antidepressant: it is a useful probe for separating receptor-driven signaling, sedation, exposure, and cell-level effects. This article translates the seminal placebo-controlled trial into practical assay logic for neuroscience and antipathogenic research.

• PreScission Protease for Nuclear Architecture Assays

  2026-08-30

  PreScission Protease enables precise HRV 3C protease tag removal at low temperature. This article shows how tag-cleavage design can strengthen assays examining Drosophila Keap1, lamin Dm0, and chromatin organization.

• Octenidine Dihydrochloride Research Guide

  2026-08-29

  Octenidine dihydrochloride is a synthetic cationic antiseptic small molecule used as an antimicrobial agent for research. Its documented membrane-disruption rationale, product-specific solubility, and defined storage requirements support controlled laboratory assay design, but in vitro activity does not establish clinical or diagnostic use.

8101 records 1/541 page Next 12345 下5页 Last page